Drug Profile
CBL 514
Alternative Names: CBL-514Latest Information Update: 30 Apr 2024
Price :
$50
*
At a glance
- Originator Caliway Biopharmaceuticals Australia
- Class Obesity therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants; Lipolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adiposis dolorosa; Cellulite; Obesity; Subcutaneous fat disorders
Most Recent Events
- 25 Apr 2024 Topline adverse events and efficacy data from the phase-II CBL0201EFP trial in Cellulite released by Caliway Biopharmaceuticals
- 04 Mar 2024 CBL 514 receives Orphan Drug status for Adiposis dolorosa in USA
- 14 Feb 2024 CBL 514 receives Fast Track designation for Adiposis dolorosa [SC,Injection] in USA